ReviewBiomolecules & therapeutics2018
Towards the Application of Human Defensins as Antivirals.
Review in Biomolecules & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 83 citations in OpenAlex.
- Mental Health, Mucosal Immunity, and HIV Susceptibility Following Sexual Violence: Evidence from the THRIVE Study.Viruses · 2026Article
- Synthetic host defense peptide inhibits SARS-CoV-2 replicationAntimicrobial agents and chemotherapy · 2025Article
- Design a multi-epitope vaccine candidate against Acinetobacter baumannii using advanced computational methods.AMB Express · 2025Article
- Advances in the Role of Antimicrobial Peptides in the Management of Sexually Transmitted Infections.Journal of clinical laboratory analysis · 2025Review
- Human Defensins: Structure, Function, and Potential as Therapeutic Antimicrobial Agents with Highlights Against SARS CoV-2.Probiotics and antimicrobial proteins · 2025Review
- Computational design and evaluation of multiepitope vaccines against herpes simplex virus type 1.Frontiers in immunology · 2025Article
- A comprehensive strategy for the development of a multi-epitope vaccine targetingFrontiers in microbiology · 2025Article
- In Vitro Profiling of the Antiviral Peptide TAT-I24.International journal of molecular sciences · 2024Article
- Antimicrobial Peptides (AMPs) and the Microbiome in Preterm Infants: Consequences and Opportunities for Future Therapeutics.International journal of molecular sciences · 2024Review
- Designing a smallpox B-cell and T-cell multi-epitope subunit vaccine using a comprehensive immunoinformatics approach.Microbiology spectrum · 2024Article
- Brilacidin as a Broad-Spectrum Inhibitor of Enveloped, Acutely Infectious Viruses.Microorganisms · 2023Article
- Local Immune Biomarker Expression Depending on the Uterine Microbiota in Patients with Idiopathic Infertility.International journal of molecular sciences · 2023Article
- Altered Expression of Antimicrobial Peptides in the Upper Gastrointestinal Tract of Patients with Diabetes Mellitus.Nutrients · 2023Article
- Evaluation of human β‑defensins in the cerebrospinal fluid of suspected meningitis.Biomedical reports · 2023Article
- Role of defensins in diabetic wound healing.World journal of diabetes · 2022Review
- Protein-bound sialic acid in saliva contributes directly to salivary anti-influenza virus activity.Scientific reports · 2022Article
- Host Defence Peptides: A Potent Alternative to Combat Antimicrobial Resistance in the Era of the COVID-19 Pandemic.Antibiotics (Basel, Switzerland) · 2022Review
- Development of Peptide Biopharmaceuticals in Russia.Pharmaceutics · 2022Review
- Immunomodulatory and Allergenic Properties of Antimicrobial Peptides.International journal of molecular sciences · 2022Review
- Defensins: Therapeutic molecules with potential to treat SARS-CoV-2 infection.The Indian journal of medical research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Defensins are antimicrobial peptides that participate in the innate immunity of hosts. Humans constitutively and/or inducibly express α- and β-defensins, which are known for their antiviral and antibacterial activities. This review describes the application of human defensins. We discuss the extant experimental results, limited though they are, to consider the potential applicability of human defensins as antiviral agents. Given their antiviral effects, we propose that basic research be conducted on human defensins that focuses on RNA viruses, such as human immunodeficiency virus (HIV), influenza A virus (IAV), respiratory syncytial virus (RSV), and dengue virus (DENV), which are considered serious human pathogens but have posed huge challenges for vaccine development for different reasons. Concerning the prophylactic and therapeutic applications of defensins, we then discuss the applicability of human defensins as antivirals that has been demonstrated in reports using animal models. Finally, we discuss the potential adjuvant-like activity of human defensins and propose an exploration of the 'defensin vaccine' concept to prime the body with a controlled supply of human defensins. In sum, we suggest a conceptual framework to achieve the practical application of human defensins to combat viral infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.